Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd rose for a third straight session today. The stock is quoting at Rs 2443.1, up 1.8% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.23% on the day, quoting at 24277.5. The Sensex is at 77643.06, down 0.02%. Glenmark Pharmaceuticals Ltd has added around 11.25% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has added around 2.83% in last one month and is currently quoting at 26564, up 0.43% on the day. The volume in the stock stood at 3.53 lakh shares today, compared to the daily average of 5.16 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 2456.5, up 2.06% on the day. Glenmark Pharmaceuticals Ltd is up 26.13% in last one year as compared to a 0.91% fall in NIFTY and a 22.33% fall in the Nifty Pharma index.The PE of the stock is 46.3 based on TTM earnings ending June 26.

Glenmark Pharmaceuticals Limited announced the allotment of 23,863 equity shares on August 10, 2026, under its Employee Stock Option Plan 2016 (ESOP 2016), increasing the company's paid-up capital from Rs 28,22,00,809 to Rs 28,22,24,672 and the total number of equity shares from 28,22,00,809 to 28,22,24,672.

Glenmark Pharmaceuticals Ltd share price declined by 3.13% to Rs 2191.05. The Company's net profit saw a strong growth of 60.24% to Rs 482.83 crore, while revenue from operations improved marginally 4.56% to Rs 3931.73 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, gaining 6%. It has inched up 2.79% over last one week and surged by 15.59% in last one month while the market capitalization of Glenmark Pharmaceuticals Ltd has improved by 1.83% and 7.16% in the same period respectively. Profit before tax (PBT) of Glenmark Pharmaceuticals Ltd stood at Rs 643.39 crore in Q2 FY26, expanding by 573.14% year-on-year, and rallying 65.92% quarter-on-quarter. EBITDA came in at Rs 739 crore, surging by 33.38% YoY and jumping 28.86% sequentially. Total expenses grew marginally by 7.32% to Rs 3386.86 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 601.07 crore, falling by 17.80% YoY, while employee benefits expense was at Rs 934.7 crore, easing 5.33% YoY. For the TTM ended FY26, revenue from operations improved 12.98% to Rs 13145.84 crore, while net profit witnessed a sharp fall of 157.19% to Rs 1047.14 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 25845% to Rs 2237.66 crore, and PBT surged 3733.45% to Rs 1399.21 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 827.6 crore in FY26, as against Rs 265.44 crore in FY25. Glenmark Pharmaceuticals Ltd gained 1.66% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 4.36% during the same period.

Immunogenics, Inc. continues to advance its pipeline of multispecific therapeutics, highlighted by the Phase 1 dose expansion trial for ISB 2001/ABBV-2001, a trispecific antibody for multiple myeloma, currently underway in Australia, the US, and Europe. The company has collaborations with AbbVie for North America, Europe, Japan, and Greater China, and Glenmark for Emerging Markets, potentially yielding up to $1.225 billion in milestone payments and royalties. Other programs include ISB 2301, a multispecific immune cell activator targeting solid tumors, slated for an Investigational New Drug application this year, and ISB 880/LAD191, an IL-1RAP antagonist in Phase 2 trials for hidradenitis suppurativa, licensed to Almirall. Further development is underway for ISB 830 and its extended-half-life version, STAR-0310, now under BioCryst following the acquisition of Astria Therapeutics.

Glenmark Specialty S.A. (Glenmark) today announced that U.S. FDA has approved the expanded use of RYALTRIS' (olopatadine hydrochloride and mometasone furoate) Nasal Spray, 665 mcg/25 mcg per spray, for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years. With this approval, RYALTRIS' is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population.

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 31 July 2026.

Glenmark Pharmaceuticals Ltd gained for a fifth straight session today. The stock is quoting at Rs 2307, up 0.08% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.45% on the day, quoting at 24160.1. The Sensex is at 77455.4, up 0.52%. Glenmark Pharmaceuticals Ltd has risen around 6.97% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has risen around 7.92% in last one month and is currently quoting at 25907.1, up 0.64% on the day. The volume in the stock stood at 2.35 lakh shares today, compared to the daily average of 5.85 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 2315.7, up 0.36% on the day. Glenmark Pharmaceuticals Ltd is up 4.64% in last one year as compared to a 4.17% drop in NIFTY and a 15.39% drop in the Nifty Pharma index.The PE of the stock is 40.66 based on TTM earnings ending March 26.Powered by Capital Market - Live

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 2260.5, up 2.24% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.68% on the day, quoting at 24436.8. The Sensex is at 78319.33, up 0.71%. Glenmark Pharmaceuticals Ltd has gained around 3.86% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 6.64% in last one month and is currently quoting at 25745.15, up 0.02% on the day. The volume in the stock stood at 3.7 lakh shares today, compared to the daily average of 5.9 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 2272.5, up 2.24% on the day. Glenmark Pharmaceuticals Ltd is up 21.53% in last one year as compared to a 4.02% slide in NIFTY and a 15.14% slide in the Nifty Pharma index.The PE of the stock is 38.97 based on TTM earnings ending March 26.Powered by Capital Market - Live

The company said the product is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa IntraMuscular Injection 10 mg/vial, marketed by Cheplapharm Registration GmbH under NDA 021253. According to IQVIA sales data for the 12-month period ended May 2026, the reference product recorded annual sales of approximately $25.4 million in the US. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, 'The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectable portfolio and strengthening our presence within the institutional channel. It reflects our continued commitment to expanding access to quality and affordable treatment options to meet the evolving needs of patients and healthcare providers.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. The company reported a 6,381.9% zoom in consolidated net profit to Rs 301.41 crore on a 16.8% increase in revenue from operations to Rs 3,760.28 crore in Q4 FY26 over Q4 FY25. Powered by Capital Market - Live

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. Glenmark's Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa'2 IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253]. According to IQVIA' sales data for the 12-month period ending May 2026, the Zyprexa' IntraMuscular Injection market achieved annual sales of approximately $25.4 million.